• Bufalin N1507: Reliable Cell Assay Workflows

  2026-10-01

  This scenario-based guide explains how Bufalin (SKU N1507) can improve the interpretability of cell viability, proliferation, and cytotoxicity experiments. It covers formulation, vehicle controls, exposure design, mechanistic readouts, and practical criteria for selecting a well-documented Bufalin reagent.

• VX-745: Practical p38α MAPK Workflows

  2026-09-30

  VX-745 combines nanomolar p38α inhibition with a practical workflow for inflammation, aging, and multiple myeloma research. This guide connects biochemical pathway analysis to cytokine assays, cell models, and arthritis animal model planning while emphasizing controls and troubleshooting.

• Recombinant Human FGF-19 Assay Workflows

  2026-09-30

  Build reproducible receptor, proliferation, metabolic, and renal stress assays with a tag-free, E. coli-expressed FGF-19 reagent. This workflow uses the protein as a defined endocrine stimulus while translating the WIP1–p38 MAPK pyroptosis findings into carefully controlled, testable assay designs.

• FH1 (Catalog No. B3700) for iHep Maturation

  2026-09-29

  Learn how FH1 (Catalog No. B3700; SKU B3700) can support iPS-derived hepatocyte maturation while keeping viability, morphology, albumin, CYP3A4, and AFP measurements analytically distinct. This scenario-based guide covers assay design, stock handling, interpretation, vendor selection, and responsible links to emerging light-controlled gene-expression research.

• Fingolimod (FTY720) in T-Cell Trafficking Workflows

  2026-09-29

  Fingolimod (FTY720) gives researchers a controllable way to perturb S1P-dependent lymphocyte movement while measuring immune, tumor, and CNS outcomes. This practical guide pairs trafficking assays with magnetic CAR-T-mimicking strategies and provides starting parameters, controls, and troubleshooting logic.

• D-Luciferin Sodium Salt for Interpretable CAR-M Imaging

  2026-09-28

  D-Luciferin sodium salt enables ATP-dependent bioluminescence assays for tracking CAR-macrophage biology without confusing reporter light with therapeutic function. This guide develops an assay-design framework inspired by recent mRNA-LNP CAR-M research, emphasizing normalization, controls, and mechanistic interpretation.

• SARS-CoV-2 NSP15 Screening: Thymopentin and Oleuropein

  2026-09-28

  A 2021 structure-based virtual screen prioritized thymopentin and oleuropein as candidate binders of the SARS-CoV-2 endoribonuclease NSP15, with molecular-dynamics simulations used to examine predicted complex stability. The results provide a computational starting point for experimental testing, not evidence of antiviral efficacy or clinically validated NSP15 inhibition.

• CDK9 inhibitor A3294: Practical Protocol and QC

  2026-09-27

  CDK9 inhibitor A3294 provides a selective way to investigate CDK9-dependent transcription elongation and defined HIV-1 research workflows. Its biochemical potency and selectivity data are product-dossier values, not a substitute for cell-specific dose finding; it is not a pan-CDK reagent or evidence of broad cytotoxicity or antiviral efficacy.

• Thiazovivin: Practical ROCK Inhibitor Workflow

  2026-09-26

  Thiazovivin is a ROCK inhibitor used to support human embryonic stem cell survival after trypsinization and to improve fibroblast reprogramming efficiency in iPSC workflows. Use it as a research reagent with an empirically optimized protocol; the product information does not establish a universal dose or exposure time, and it is not for diagnostic or medical use.

• Machine Learning Designs mRNA LNPs for Microglia

  2026-09-25

  Rafiei, Shojaei, and Chau combined a 216-formulation lipid nanoparticle library with supervised machine learning to study mRNA delivery and inflammatory phenotypes in microglia. Their results identify an HA-modified formulation that delivered IL10 mRNA and reduced inflammatory readouts in cell models, while also showing that model performance depends on microglial activation state.

• Mdivi-1 in Mitochondrial Dynamics Research

  2026-09-25

  Mdivi-1 is a cell-permeable selective DRP1 inhibitor used to investigate mitochondrial fission, apoptosis, and neuroprotection. A 2026 chronic intermittent hypoxia study reports that Mdivi-1 mitigated lung apoptosis-associated changes and mitochondrial injury, while its results should be interpreted within that experimental model.

• EdU Flow Cytometry Assay Kits for Vascular Studies

  2026-09-24

  Track S-phase entry in hypoxia-responsive endothelial and smooth muscle cell models without DNA-denaturation steps. Pair EdU labeling with carefully matched controls to distinguish altered DNA synthesis from changes in cell survival or cell-cycle composition.

• Faropenem Sodium: Mechanism, Evidence & Research Use

  2026-09-24

  Faropenem sodium is a penem antibiotic described as inhibiting bacterial cell-wall synthesis and acting across Gram-positive, Gram-negative, and anaerobic bacteria. Product information reports formulation properties and antimicrobial benchmarks, while a human NPT1 study shows faropenem transport in an experimental cell system—not clinical renal clearance.

• RITA (NSC 652287): Read Drug Response Beyond IC50

  2026-09-23

  RITA (NSC 652287) offers a useful case study in why a single viability value can obscure how cancer cells respond to treatment. This article connects its reported p53 activity and DNA cross-linking with practical choices for measuring growth arrest, cell death, and response timing.

• SmD2 Acetylation and PARP Inhibitor Sensitivity in HCC

  2026-09-23

  A 2024 Nature Communications study identifies acetylation-dependent control of the spliceosome protein SmD2 as a mechanism linking alternative splicing, BRCA1/FANC expression, DNA damage repair, and PARP inhibitor response in hepatocellular carcinoma. The work supports combining HDAC-axis modulation with PARP inhibition, while indicating that spliceosome state may be an important determinant of treatment sensitivity.

8440 records 1/563 page Next 12345 下5页 Last page